IgG Study of Blood Sera of Patients with COVID-19

The COVID-19 pandemic, which began at the end of 2019 in Wuhan, has affected 220 countries and territories to date. In the present study, we studied humoral immunity in samples of the blood sera of COVID-19 convalescents of varying severity and patients who died due to this infection, using native S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elena Kazachinskaia, Alexander Chepurnov, Dmitry Shcherbakov, Yulia Kononova, Teresa Saroyan, Marina Gulyaeva, Daniil Shanshin, Valeriya Romanova, Olga Khripko, Michail Voevoda, Alexander Shestopalov
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 antibody specificity recombinant proteins virus neutralization Medicine R
Acceso en línea:	https://doaj.org/article/4d1ccb0a899f44329cd1aaa17ec6c057
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d1ccb0a899f44329cd1aaa17ec6c057
record_format	dspace
spelling	oai:doaj.org-article:4d1ccb0a899f44329cd1aaa17ec6c0572021-11-25T18:38:08ZIgG Study of Blood Sera of Patients with COVID-1910.3390/pathogens101114212076-0817https://doaj.org/article/4d1ccb0a899f44329cd1aaa17ec6c0572021-11-01T00:00:00Zhttps://www.mdpi.com/2076-0817/10/11/1421https://doaj.org/toc/2076-0817The COVID-19 pandemic, which began at the end of 2019 in Wuhan, has affected 220 countries and territories to date. In the present study, we studied humoral immunity in samples of the blood sera of COVID-19 convalescents of varying severity and patients who died due to this infection, using native SARS-CoV-2 and its individual recombinant proteins. The cross-reactivity with SARS-CoV (2002) was also assessed. We used infectious and inactivated SARS-CoV-2/human/RUS/Nsk-FRCFTM-1/2020 strain, inactivated SARS-CoV strain (strain Frankfurt 1, 2002), recombinant proteins, and blood sera of patients diagnosed with COVID-19. The blood sera from patients were analyzed by the Virus Neutralization test, Immunoblotting, and ELISA. The median values and mean ± SD of titers of specific and cross-reactive antibodies in blood sera tested in ELISA were mainly distributed in the following descending order: N > trimer S > RBD. ELISA and immunoblotting revealed a high cross-activity of antibodies specific to SARS-CoV-2 with the SARS-CoV antigen (2002), mainly with the N protein. The presence of antibodies specific to RBD corresponds with the data on the neutralizing activity of blood sera. According to the neutralization test in a number of cases, higher levels of antibodies that neutralize SARS-CoV-2 were detected in blood serum taken from patients several days before their death than in convalescents with a ranging disease severity. This high level of neutralizing antibodies specific to SARS-CoV-2 in the blood sera of patients who subsequently died in hospital from COVID-19 requires a thorough study of the role of humoral immunity as well as comorbidity and other factors affecting the humoral response in this disease.Elena KazachinskaiaAlexander ChepurnovDmitry ShcherbakovYulia KononovaTeresa SaroyanMarina GulyaevaDaniil ShanshinValeriya RomanovaOlga KhripkoMichail VoevodaAlexander ShestopalovMDPI AGarticleSARS-CoV-2COVID-19antibody specificityrecombinant proteinsvirus neutralizationMedicineRENPathogens, Vol 10, Iss 1421, p 1421 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 antibody specificity recombinant proteins virus neutralization Medicine R
spellingShingle	SARS-CoV-2 COVID-19 antibody specificity recombinant proteins virus neutralization Medicine R Elena Kazachinskaia Alexander Chepurnov Dmitry Shcherbakov Yulia Kononova Teresa Saroyan Marina Gulyaeva Daniil Shanshin Valeriya Romanova Olga Khripko Michail Voevoda Alexander Shestopalov IgG Study of Blood Sera of Patients with COVID-19
description	The COVID-19 pandemic, which began at the end of 2019 in Wuhan, has affected 220 countries and territories to date. In the present study, we studied humoral immunity in samples of the blood sera of COVID-19 convalescents of varying severity and patients who died due to this infection, using native SARS-CoV-2 and its individual recombinant proteins. The cross-reactivity with SARS-CoV (2002) was also assessed. We used infectious and inactivated SARS-CoV-2/human/RUS/Nsk-FRCFTM-1/2020 strain, inactivated SARS-CoV strain (strain Frankfurt 1, 2002), recombinant proteins, and blood sera of patients diagnosed with COVID-19. The blood sera from patients were analyzed by the Virus Neutralization test, Immunoblotting, and ELISA. The median values and mean ± SD of titers of specific and cross-reactive antibodies in blood sera tested in ELISA were mainly distributed in the following descending order: N > trimer S > RBD. ELISA and immunoblotting revealed a high cross-activity of antibodies specific to SARS-CoV-2 with the SARS-CoV antigen (2002), mainly with the N protein. The presence of antibodies specific to RBD corresponds with the data on the neutralizing activity of blood sera. According to the neutralization test in a number of cases, higher levels of antibodies that neutralize SARS-CoV-2 were detected in blood serum taken from patients several days before their death than in convalescents with a ranging disease severity. This high level of neutralizing antibodies specific to SARS-CoV-2 in the blood sera of patients who subsequently died in hospital from COVID-19 requires a thorough study of the role of humoral immunity as well as comorbidity and other factors affecting the humoral response in this disease.
format	article
author	Elena Kazachinskaia Alexander Chepurnov Dmitry Shcherbakov Yulia Kononova Teresa Saroyan Marina Gulyaeva Daniil Shanshin Valeriya Romanova Olga Khripko Michail Voevoda Alexander Shestopalov
author_facet	Elena Kazachinskaia Alexander Chepurnov Dmitry Shcherbakov Yulia Kononova Teresa Saroyan Marina Gulyaeva Daniil Shanshin Valeriya Romanova Olga Khripko Michail Voevoda Alexander Shestopalov
author_sort	Elena Kazachinskaia
title	IgG Study of Blood Sera of Patients with COVID-19
title_short	IgG Study of Blood Sera of Patients with COVID-19
title_full	IgG Study of Blood Sera of Patients with COVID-19
title_fullStr	IgG Study of Blood Sera of Patients with COVID-19
title_full_unstemmed	IgG Study of Blood Sera of Patients with COVID-19
title_sort	igg study of blood sera of patients with covid-19
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4d1ccb0a899f44329cd1aaa17ec6c057
work_keys_str_mv	AT elenakazachinskaia iggstudyofbloodseraofpatientswithcovid19 AT alexanderchepurnov iggstudyofbloodseraofpatientswithcovid19 AT dmitryshcherbakov iggstudyofbloodseraofpatientswithcovid19 AT yuliakononova iggstudyofbloodseraofpatientswithcovid19 AT teresasaroyan iggstudyofbloodseraofpatientswithcovid19 AT marinagulyaeva iggstudyofbloodseraofpatientswithcovid19 AT daniilshanshin iggstudyofbloodseraofpatientswithcovid19 AT valeriyaromanova iggstudyofbloodseraofpatientswithcovid19 AT olgakhripko iggstudyofbloodseraofpatientswithcovid19 AT michailvoevoda iggstudyofbloodseraofpatientswithcovid19 AT alexandershestopalov iggstudyofbloodseraofpatientswithcovid19
_version_	1718410890503520256

IgG Study of Blood Sera of Patients with COVID-19

Ejemplares similares